Investigator's Global Assessment of Chronic Prurigo: A New Instrument for Use in Clinical Trials.

"Conflicts of interest. CZ reports personal fees from Beiersdorf and Dermasence and is a investigator for Sanofi, Abbvie, Boerhinger Ingelheim, Novartis, MSD, Pfizer outside the submitted work. MPP reports personal fees from Galderma, personal fees from Menlo Therapeutics, personal fees from Trevi Therapeutics, personal fees from Novartis outside the submitted work. MA reports grants and personal fees from Abbott/AbbVie, Amgen, Biogen Idec, Boehringer Ingelheim, Celgene, Centocor, Eli Lilly, Forward Pharma, Galderma, GSK, Hexal, Janssen, LEO Pharma, Medac, MSD, Novartis, Pfizer, Sandoz, Teva, TK, Trevi, and Xenoport. outside the submitted work. SS reports personal fees from Almirall, personal fees from Beiersdorf, personal fees from Bellus Health, personal fees from Cara Therapeutics, personal fees from Celgene, personal fees from Galderma Laboratorium, personal fees from Clexio Biosciences, personal fees from LEO, personal fees from Menlo Therapeutics, personal fees from Novartis, personal fees from Sienna Biopharmaceuticals, personal fees from Trevi Therapeutics, personal fees from Vanda Pharmaceuticals, other from Dermasence, other from Kiniksa, other from Galderma, personal fees from Galderma S.A., other from Menlo Therapeutics, other from Novartis, other from Trevi Therapeutics, outside the submitted work. MS has no conflicts of interest to declare."

"We acknowledge the support provided by the European Academy of Dermatology and Venereology (EADV, number 2016-012 to MP)."

"After providing written informed consent, 187 consecutive adult patients with CPG (clinically and histologically confirmed) were included in this prospective, longitudinal, uncontrolled, non-interventional study between November 2017 and February 2020. The ethics committee of the University of Münster approved the study, which was registered in the German Clinical Trials Register (DRKS00005383). Three trained investigators completed the IGA – chronic prurigo (IGA-CPG) stage, IGA – chronic nodular prurigo (IGA-CNPG) stage and IGA-CPG activity () and then counted all pruriginous lesions (papules, nodules, ulcers, plaques) in each patient. Patients completed electronically itch intensity scales (on a numerical rating scale (NRS): worst itch in the previous 24 h and in the previous 4 weeks) and instruments measuring the impairment in quality of life (Dermatology Quality of Life Index (DLQI) () and ItchyQoL)."